What the business is, and whether it's a good one at a fair price.
A Pharmaceuticals & Biotechnology company listed on NSE and BSE, reporting revenue of ₹4,502 Cr over the trailing twelve months.
Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice
How has the market priced it — with filings on the timeline?
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
How does it stack up on valuation, returns and growth?
Loading peers…
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Answered from AKUMS DRUGS AND PHARMA L's filed financials and exchange disclosures
AKUMS DRUGS AND PHARMA L is a Pharmaceuticals & Biotechnology company listed on NSE and BSE, trading under the symbol AKUMS.
Yes. Over the trailing twelve months AKUMS DRUGS AND PHARMA L reported a net profit of ₹293 Cr on revenue of ₹4,502 Cr.
Not in the latest reported year — AKUMS DRUGS AND PHARMA L's dividend payout for FY26 was nil.
Effectively yes. It holds ₹313 Cr more cash than debt. Debt stands at 0.02× equity.
On trailing P/E, AKUMS DRUGS AND PHARMA L ranks 112 of 169 in Pharmaceuticals — cheaper than 34% of them, against an industry median of 28.9×. This is a position, not a valuation judgement.
On a typical session AKUMS DRUGS AND PHARMA L moves 1.17% — that is the median absolute close-to-close move across its last 269 trading days. Announcement days are routinely larger.
Every NSE and BSE filing by AKUMS DRUGS AND PHARMA L appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.
